

**ANTIESTROGENS FOR THE HORMONE THERAPY OF BREAST
CANCER: ANALYSIS OF ECONOMIC AVAILABILITY AND
VOLUME OF CONSUMPTION**

Mishchenko O. Ya., Greshko Iu. I., Adonkina V. Yu.

National Pharmaceutical University, Ukraine

oksanamishch2021@gmail.com

Around the world and in Ukraine, breast cancer has taken the first place among all oncological diseases and in the structure of women's mortality in recent decades. Breast cancer is a heterogeneous disease that includes different variants of tumors, but among all phenotypes, the so-called luminal (in which the expression of receptors for estrogen (ER) and / or progesterone) and the absence of expression of receptors for epidermal growth factor (HER2-negative) prevail tumors, the specific weight of which in the structure of all phenotypes of breast cancer reaches 70%. Today, approaches to the treatment of ER(+) HER2(-) breast cancer are determined based on the principles of evidence-based medicine and include the use of anti-estrogen drugs and inhibitors aromatase. Treatment of patients with breast cancer using anti-estrogens, namely tamoxifen, toremifene and fulvestrant, remains one of the most effective.

The aim is to study the economic availability and consumption volumes of anti-estrogens for hormone therapy of ER(+) HER2(-) breast cancer.

Materials and methods: a retrospective analysis of the assortment, prices, economic availability and consumption volumes of hormone therapy for ER(+) HER2(-) breast cancer presented in the pharmaceutical market of Ukraine in 2017-2022.

Results. In the pharmaceutical market of Ukraine in 2017-2022, 3 INNs of antiestrogens were presented during the entire period under study: tamoxifen (L02BA01), toremifene (L02B A02) and fulvestrant (L02B A03). The index of solvency adequacy (Ca.s.) during 2017-2022 for tamoxifen drugs was < 5%, for part of toremifene drugs it was 3.26–4.10%, and for another part - 12.4–19.7%, for fulvestrant drugs – 50.6–265.5%. The number of sold packages of anti-estrogens was 187,8; 186,86; 182,9; 168,4; 164,0; 153,14 thousand, respectively, during 2017-2022. Tamoxifen is the leader in terms of consumption, but its consumption has been decreasing over the years, while fulvestrant has been increasing.

Conclusions: In the Ukrainian pharmaceutical market in 2017-2022, anti-estrogens for hormone therapy of ER(+) HER2(-) breast cancer were represented by 3 INNs: tamoxifen, toremifene, and fulvestrant. It was established that almost all tamoxifen drugs are highly available to the Ukrainian consumer, toremifene is mostly not available, and fulvestrant drugs are the most inaccessible. There is a trend towards a decrease in the consumption of drugs from the group of anti-estrogens, to a greater extent due to a decrease in the consumption of tamoxifen drugs.